Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

CG Oncology (CGON) Research & Development (2023 - 2025)

CG Oncology's Research & Development history spans 3 years, with the latest figure at $30.0 million for Q4 2025.

  • For Q4 2025, Research & Development rose 11.78% year-over-year to $30.0 million; the TTM value through Dec 2025 reached $116.6 million, up 42.07%, while the annual FY2025 figure was $116.6 million, 42.07% up from the prior year.
  • Research & Development reached $30.0 million in Q4 2025 per CGON's latest filing, up from $27.9 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $31.3 million in Q2 2025 to a low of $7.8 million in Q1 2023.
  • Average Research & Development over 3 years is $20.4 million, with a median of $19.0 million recorded in 2024.
  • Peak YoY movement for Research & Development: soared 119.46% in 2024, then grew 11.78% in 2025.
  • A 3-year view of Research & Development shows it stood at $16.3 million in 2023, then surged by 64.01% to $26.8 million in 2024, then grew by 11.78% to $30.0 million in 2025.
  • Per Business Quant, the three most recent readings for CGON's Research & Development are $30.0 million (Q4 2025), $27.9 million (Q3 2025), and $31.3 million (Q2 2025).